Phase 2 Crohn's Disease and Colitis Trial, Recruiting NCT06619990 Sponsor: Xencor, Inc. Condition: Crohn's Disease and Colitis
Back to Crohns Disease And Colitis

Phase 2 Crohn's Disease and Colitis Trial, Recruiting

NCT06619990
Recruiting Phase 2 🇦🇺 Australian site

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

For Parts A and B (healthy volunteers, ages 18–55):

  • You are between 18 and 55 years old
  • You are in good general health with no significant medical history
  • Your routine blood and lab test results are within the normal range
  • Your Body Mass Index (BMI) is between 18 and 35
  • You are willing to use contraception as required by local guidelines (applies to both men and women)
  • You are able and willing to sign a consent form agreeing to take part

For Part C (patients with ulcerative colitis, ages 18–75):

  • You are between 18 and 75 years old
  • You are in good general health aside from your ulcerative colitis
  • You have been diagnosed with ulcerative colitis for at least 3 months before the screening visit
  • Your ulcerative colitis is currently moderately to severely active, based on specific scoring measures (confirm with trial site)
  • Your ulcerative colitis affects a significant portion of your colon, confirmed by a colonoscopy at screening (confirm with trial site)
  • Previous treatments for ulcerative colitis have not worked well enough, have stopped working, or you were unable to tolerate them
  • You are able and willing to sign a consent form agreeing to take part

Who may not be able to join:

For Parts A and B:

  • You have any physical or mental health condition that would prevent you from completing the study
  • You have a history of suicidal thoughts or behavior
  • You are a heavy user of nicotine-containing products (e.g., cigarettes, vapes)
  • You have tested positive for HIV, hepatitis B, or hepatitis C
  • You have an irregular heartbeat or an abnormal heart tracing (ECG)
  • You have used prescription medications in the 14 days before the study starts
  • You have used any over-the-counter or herbal medicines in the 7 days before screening
  • You have taken part in another clinical trial within the last 30 days
  • You have donated blood or plasma within the last 60 days
  • You are pregnant or breastfeeding

For Part C:

  • You have any physical or mental health condition that would prevent you from taking part in the study
  • You have been diagnosed with Crohn's disease or another type of colitis other than ulcerative colitis (such as microscopic, ischemic, infectious, or radiation-related colitis)
  • You have tested positive for a gut infection called Clostridioides difficile (C. diff)
  • You have tested positive for HIV, hepatitis B, or hepatitis C
  • You have an irregular heartbeat or an abnormal heart tracing (ECG)
  • You are pregnant or breastfeeding

Important: Always verify eligibility with the trial site directly before applying. Additional criteria not listed here may also apply.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 20 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Mark Osterman, MD, MSCE, Xencor, Inc.

Australian sites

Xencor Investigative Site, Wollongong, New South Wales
Xencor Investigative Site, South Brisbane, Queensland
Xencor Investigative Site, Southport, Queensland
Xencor Investigative Site, Joondalup, Western Australia
Xencor Investigative Site, Nedlands, Western Australia

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Xencor, Inc.
Registry
ClinicalTrials.gov
Start date
10 October 2024
Est. completion
1 April 2028

Where this trial is recruiting

🇦🇺 Australia 🇧🇬 Bulgaria 🇨🇦 Canada 🇭🇷 Croatia 🇬🇪 Georgia 🇬🇷 Greece 🇭🇺 Hungary Moldova 🇵🇱 Poland 🇷🇴 Romania 🇺🇦 Ukraine 🇺🇸 United States

5 site(s) in Australia. Confirm current status and contact details directly with the trial site.

Primary endpoints

Incidence, nature, and severity of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs) of XmAb942 in healthy volunteers (Part A); Incidence, nature, and severity of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs) of XmAb942 in healthy volunteers (Part B); Clinical remission based on modified mayo score (MMS), defined as MMS ≤ 2 with Mayo endoscopic score (MES) of 1, rectal bleeding subscore (RBS) of 0, and stool frequency subscore (SFS) of 0-1.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov